DOCSLIB.ORG

Comparing Psychopharmacological Prescriber Training Models Via Examination of Content-Based Knowledge

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Comparing Psychopharmacological Prescriber Training Models Via Examination of Content-Based Knowledge Comparing Psychopharmacological Prescriber Training Models via Examination of Content-Based Knowledge The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Cooper, Ryan R. 2020. Comparing Psychopharmacological Prescriber Training Models via Examination of Content-Based Knowledge. Master's thesis, Harvard Extension School. Citable link https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37365636 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use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`?16(1>,!A%%'#&./!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!]J! !!!!!!!!!!!!!!!!!!!!_9/1'!A%%'#&./1,!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!]a! !!!!!!!!!!A!4#'1!C('1.9!A%%'#&./!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!]^! !!!!!!!!!!E(*)(:(.&).1!#:!E9F5-!b!G-%#9/1,1,!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!]c! ZZ@!419/#5!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!]X! !!!!!!!!!!+&'9(.(%&)9,!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!]X! !!!!!!!!!!41&,F'1,!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!J]! !!!!!!!!!!+'#.15F'1,!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!JJ! !!!!!!!!!!C&9&!A)&0-,(,!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!Jd! ZZZ@!?1,F09,!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!J^! !!!!!!!!!!C1,.'(%9(61!E9&9(,9(.,!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!J^! ! "!!# !!!!!!!!!!31,9()*!#:!G-%#9/1,1,!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!Jc! !!!!!!!!!!A)&0-,(,!b!+#,9!/#.!A)&0-,(,!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!JW! Ze@!C(,.F,,(#)!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!d]! !!!!!!!!!!A%%0(15!B()5()*,!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!dd! !!!!!!!!!!D($(9&9(#),!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!d^! !!!!!!!!!!!!!!!!!!!!?#2F,9)1,,!#:!78&$()&9(#)!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!d^! !!!!!!!!!!!!!!!!!!!!3/1!"#$%191).-!f<0F'g!b!3($1;Z);+'&.9(.1!C(::1'1).1,!!@@@@@@@@@@@@@@@@@@@@@@@@@!dT! !!!!!!!!!!!!!!!!!!!!=)#>015*1!6,@!hF&0(9-!#:!"&'1!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!dc! !!!!!!!!!!!!!!!!!!!!78&$()11!A991)9(61)1,,!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!dW! !!!!!!!!!!!!!!!!!!!!E101.9(#)!<(&,!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!dW! !!!!!!!!!!!!!!!!!!!!E9&9(,9(.&0!A,,F$%9(#),!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!dX! !!!!!!!!!!BF9F'1!C('1.9(#),!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!dX! ?1:1'1).1,!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!aa! A%%1)5(.1,!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!aX! !!!!!!!!!!A%%1)5(8!AU!78&$()&9(#)!hF1,9(#),!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!aX! !!!!!!!!!!A%%1)5(8!<U!"#),1)9!b!Z),9'F.9(#),!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!TJ! !!!!!!!!!!A%%1)5(8!"U!C12'(1:()*!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!Ta! !!!!!!!!!!A%%1)5(8!CU!i'(91;Z)!A),>1'!?16(1>!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!T^! !!!!!!!!!!! ! ! ! ! ! "!!!# ! D(,9!#:!3&201,! ! 3&201!]U!A00!*'#F%!51,.'(%9(61,!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!Jc! 3&201!JU!31,9!#:!I#'$&0(9-!ME/&%('#;i(0SN!!@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@@!JW!
Load more

Recommended publications
  • CPT Fellowship Psychopharm Focus
    Clinical Pharmacology and Toxicology Residency Program, McGill University One year Fellowship in Clinical Pharmacology and Toxicology: Psychopharmacology Focus Fellowship Director: Dr. Theodore Kolivakis, MD, FRCPC Program Director: Dr. Howard Margolese Location: MUHC (70-90%) JGH (10-20%) DH (10-20%) (% Depends on Selectives chosen based on interest of the Fellow) Number of Positions: 1 Length of Program: 1 year. The ‘academic’ year is July 1 to June 30, however ‘off-cycle’ candidates will also be considered Program General Information: The Clinical Pharmacology and Toxicology Fellowship: Psychopharmacology Focus is a one-year supervised training program open to qualified psychiatry residents who have completed their Psychiatry Postgraduate training and are eligible for practice in Canada. This fellowship program is based in the Clinical Psychopharmacology and Therapeutics Unit of the McGill University Health Centre (MUHC), Department of Psychiatry, McGill University, and is carried out in collaboration with a number of University hospitals and centers, namely the Clinical Toxicology Service of the MUHC, Alan Edwards Centre for Research on Pain at the MUHC, Internal Medicine at the MUHC or JGH (Hypertension clinic), Douglas Mental Health University Institute, and the Montreal Neurological Hospital and Institute; as well as the Department of Pharmacy of the MUHC. The objective of this program is to provide advanced training in clinical pharmacology and toxicology with a psychopharmacology focus to residents interested in gaining an expertise in the pharmacological treatment of their patients. Specifically they will learn best practices for 1. patients with complex medication regimes, 2. treatment resistant patients, 3. adverse drug reactions including iatrogenic ADR 4. consultation based care and practices After successfully completing the fellowship it is expected that fellows will become experts in the management of the most difficult psychiatric patients who are often those with significant other medical co-morbidities.
    [Show full text]
  • Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development
    Clinical Pharmacology 1: Phase 1 Studies and Early Drug Development Gerlie Gieser, Ph.D. Office of Clinical Pharmacology, Div. IV Objectives • Outline the Phase 1 studies conducted to characterize the Clinical Pharmacology of a drug; describe important design elements of and the information gained from these studies. • List the Clinical Pharmacology characteristics of an Ideal Drug • Describe how the Clinical Pharmacology information from Phase 1 can help design Phase 2/3 trials • Discuss the timing of Clinical Pharmacology studies during drug development, and provide examples of how the information generated could impact the overall clinical development plan and product labeling. Phase 1 of Drug Development CLINICAL DEVELOPMENT RESEARCH PRE POST AND CLINICAL APPROVAL 1 DISCOVERY DEVELOPMENT 2 3 PHASE e e e s s s a a a h h h P P P Clinical Pharmacology Studies Initial IND (first in human) NDA/BLA SUBMISSION Phase 1 – studies designed mainly to investigate the safety/tolerability (if possible, identify MTD), pharmacokinetics and pharmacodynamics of an investigational drug in humans Clinical Pharmacology • Study of the Pharmacokinetics (PK) and Pharmacodynamics (PD) of the drug in humans – PK: what the body does to the drug (Absorption, Distribution, Metabolism, Excretion) – PD: what the drug does to the body • PK and PD profiles of the drug are influenced by physicochemical properties of the drug, product/formulation, administration route, patient’s intrinsic and extrinsic factors (e.g., organ dysfunction, diseases, concomitant medications,
    [Show full text]
  • IJBCP International Journal of Basic & Clinical Pharmacology Antibiotic
    Print ISSN: 2319-2003 | Online ISSN: 2279-0780 IJBCP International Journal of Basic & Clinical Pharmacology DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20191567 Original Research Article Antibiotic sensitivity profile and resistance of microorganisms isolated from south Indian population, a hospital based study at Velappanchavady, Chennai, India Brethis C. S.1*, Mahender G.2, Thamizharasan S.1, Suresh Kumar K.3, Sudharson T.3 1Department of Pharmacology, A.C.S Medical College and ABSTRACT Hospital, Velappanchavadi, Chennai, Tamil Nadu, India Background: Increasing rates of antibiotic drug resistance has been noted in 2Department of Forensic recent times and this adversely affects the prognosis and outcomes of patients. Medicine and Toxicology, There is a greater need for local resistance prevalence data in order to guide District Hospital Gajwel, empirical prescription and to identify areas in which medical need for newer Telangana, India antimicrobial agents is greater. 3Department of Forensic Methods: A prospective hospital based observational study was carried out to Medicine and Toxicology, determine antibiotic sensitivity profile and resistance pattern of microorganisms. A.C.S Medical College and Samples were collected from urinary tract infections, while cultures from blood Hospital, Velappanchavadi, stream infections, sputum samples and Serology. Antibiotic susceptibility was Chennai, Tamil Nadu, India determined by the standard disc diffusion method. Data interpretation was based on CLSI, 2017 guidelines for antimicrobial susceptibility testing. Received: 14 April 2019 Results: The predominant isolates from the samples were, Staphylococcus Accepted: 19 April 2019 aureus (16.7%) 67, K. pneumoniae (11.5%) 46, E. coli (29.4%) 118, P. aeruginosa (6%) 24. Escherichia coli, the most common causative organism *Correspondence to: showed high resistance to commonly used drugs such as Ampicillin (60.1%) 71, Dr.
    [Show full text]
  • Prescriptive Authority
    5/30/2017 Prescriptive Authority: Psychologist Prescribing Why are we here? Rights: Allowing Prescribing Rights For The Latest on Legislation and Psychologists Is An Essential Step Training To Providing Thousands Of Patients With Access To Comprehensive Mental Health Care John Gavazzi, Psy.D., ABPP Tracy E. Ransom, Psy.D. Learning Objectives: 1. Describe benefits & challenges of RxP; 2. List the states that have RxP & psychologist experiences in these locations; 3. Discuss PA legislative affairs related to RxP; 4. Describe training program requirements for RxP; 5. Analyze the prescribing rights initiative through group discussion Why is RxP even a thing? Ethical aspects of RxP • Fewer psychiatrists and physicians • Beneficence across the country • Access to high quality mental • Fewer psychiatrists in rural and urban health care areas • Integration of physical and • Fewer psychiatrists take insurance psychological aspects to care: lower cost/convenience 1 5/30/2017 Some Themes to Ponder General thoughts • Organized medicine is not our enemy. • Skills Before Pills Why? • The authority to prescribe gives you the • Need to unify our organization. Why? authority to take meds away and use psychological interventions • Need a great deal of work with grassroots organizations, such as law enforcement • Psychology is the best medicine and community mental health. Why? • Psychologists are the best trained to • This will be a long-term, time consuming integrate a biopsychosocial approach. operation At a Glance Where Can Psychologists prescribe? RxP will be considered a specialty practice, in which a masters degree in psychopharmacology will be needed Louisiana Idaho Over 20 years prescribing in the military, 10+ years in New Mexico, and 10+ years in Louisiana New Mexico Indian Health Services Allowing prescribing rights for psychologists is an Illinois essential step to providing thousands of patients All Branches of the US with access to comprehensive mental health Military care.
    [Show full text]
  • Cognitive Behaviour Therapy (CBT) and Stroke Rehabilitation
    Cognitive Behaviour Therapy (CBT) and Stroke Rehabilitation Amy Quilty OT Reg. (Ont.), Occupational Therapist Cognitive Behavioural Therapy (CBT) Certificate Program, University of Toronto Quinte Health Care: [email protected] Learning Objectives • To understand that CBT: • has common ground with neuroscience • principles are consistent with stroke best practices • treats barriers to stroke recovery • is an opportunity to optimize stroke recovery Question? Why do humans dominate Earth? The power of THOUGHT • Adaptive • Functional behaviours • Health and well-being • Maladaptive • Dysfunctional behaviours • Emotional difficulties Emotional difficulties post-stroke • “PSD is a common sequelae of stroke. The occurrence of PSD has been reported as high as 30–60% of patients who have experienced a stroke within the first year after onset” Canadian Stroke Best Practice Recommendations: Mood, Cognition and Fatigue Following Stroke practice guidelines, update 2015 http://onlinelibrary.wiley.com/doi/10.1111/ijs.12557/full • Australian rates: (Kneeborne, 2015) • Depression ~31% • Anxiety ~18% - 25% • Post Traumatic Stress ~10% - 30% • Emotional difficulties post-stroke have a negative impact on rehabilitation outcomes. Emotional difficulties post-stroke: PSD • Post stroke depression (PSD) is associated with: • Increased utilization of hospital services • Reduced participation in rehabilitation • Maladaptive thoughts • Increased physical impairment • Increased mortality Negative thoughts & depression • Negative thought associated with depression has been linked to greater mortality at 12-24 months post-stroke Nursing Best Practice Guideline from RNAO Stroke Assessment Across the Continuum of Care June : http://rnao.ca/sites/rnao- ca/files/Stroke_with_merged_supplement_sticker_2012.pdf Cognitive Behavioral Therapy (CBT) https://www.youtube.com/watch?v=0ViaCs0k2jM Cognitive Behavioral Therapy - CBT A Framework to Support CBT for Emotional Disorder After Stroke* *Figure 2, Framework for CBT after stroke.
    [Show full text]
  • Clinical Pharmacology and Pharmacogenomics Fellowship Research Training
    CCPP COMMITTEE ON CLINICAL PHARMACOLOGY AND PHARMACOGENOMICS Clinical Pharmacology and Pharmacogenomics Fellowship Research Training The Committee on Clinical Pharmacology and Pharmacogenomics at the University of Chicago, chaired by M. Eileen Dolan, PhD, is seeking motivated trainees for our clinical pharmacology and pharmacogenomics fellowship training program. Candidates should have a PhD, MD, PharmD/PhD or PharmD degree and have successfully completed a clinical residency. Ability to demonstrate a commitment to research, including but not limited to evidence provided by a record of prior publication is encouraged. This program is open to those interested in personalized medicine, pharmacogenomics, new drug development, clinical pharmacology, clinical trial design, genome wide association studies, genetics of drug abuse and/or overcoming drug resistance. Our two-year American Board of Clinical Pharmacology (ABCP) accredited program is a multidisciplinary, comprehensive and collaborative initiative that emphasizes individual creativity in the context of an encouraging environment. The two-year fellowship provides salary support/benefits for protected research time dedicated to research efforts along with support to attend meetings. Trainees will have the opportunity to tailor their work to emphasize clinical, translational or basic science research spending protected time devoted to their research efforts with the remainder dedicated to core curriculum and clinical activities (as applicable). After successful completion, trainees are eligible to become board certified in Clinical Pharmacology. General information at: http://ccpp.uchicago.edu/ or contact the programs’ educational manager, Michelle Domecki at [email protected]. Candidates who are U.S. citizens or permanent residents will be considered for support via an institutional training grant. The University of Chicago is an Equal Opportunity/Affirmative Action Employer.
    [Show full text]
  • The EAT-16: Validation of a Shortened Form of the Eating Attitudes Test Elizabeth Mclaughlin
    University of New Mexico UNM Digital Repository Psychology ETDs Electronic Theses and Dissertations 9-12-2014 The EAT-16: Validation of a Shortened Form of the Eating Attitudes Test Elizabeth McLaughlin Follow this and additional works at: https://digitalrepository.unm.edu/psy_etds Recommended Citation McLaughlin, Elizabeth. "The EAT-16: Validation of a Shortened Form of the Eating Attitudes Test." (2014). https://digitalrepository.unm.edu/psy_etds/94 This Thesis is brought to you for free and open access by the Electronic Theses and Dissertations at UNM Digital Repository. It has been accepted for inclusion in Psychology ETDs by an authorized administrator of UNM Digital Repository. For more information, please contact [email protected]. i Elizabeth McLaughlin Candidate Psychology Department This thesis is approved, and it is acceptable in quality and form for publication: Approved by the Thesis Committee: Dr. Jane Ellen Smith, Chairperson Dr. Sarah Erickson Dr. Katie Witkiewitz ii THE EAT-16: VALIDATION OF A SHORTENED FORM OF THE EATING ATTITUDES TEST by ELIZABETH MCLAUGHLIN BACHELOR OF ARTS THESIS Submitted in Partial Fulfillment of the Requirements for the Degree of Master of Science Psychology The University of New Mexico Albuquerque, New Mexico July, 2014 iii ACKNOWLEDGEMENTS I’m grateful to my committee, whose guidance and direction were indispensable: Dr. Katie Witkiewitz, Dr. Sarah Erickson, and of course Dr. Jane Smith. I could imagine no better advisor than Jane to work with on this project! And I’m thankful for the encouragement I received from friends and family, both close by and far away. To my parents and my sister, Lydia: your belief in me, and your help in maintaining perspective, did so much more than you realize to carry me through the master’s process.
    [Show full text]
  • Bioavailability and Bioequivalence Studies Submitted in Ndas Or Inds — General Considerations
    Guidance for Industry Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance. Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the Federal Register. For questions regarding this draft document contact the CDER Office of Clinical Pharmacology at 301-796-5008 or [email protected]. U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) March 2014 Biopharmaceutics Guidance for Industry Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs— General Considerations Additional copies are available from: Office of Communications Division of Drug Information, WO51, Room 2201 Center for Drug Evaluation and Research Food and Drug Administration 10903 New Hampshire Avenue, Silver Spring, MD 20993 http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm Phone: 301-796-3400; Fax: 301-847-8714 [email protected] U.S. Department of Health and Human Services Food
    [Show full text]
  • Clinical Versus Counseling Psychology: What's the Diff? by John C
    Clinical Versus Counseling Psychology: What's the Diff? by John C. Norcross - University of Scranton, Fields of Psychology Graduate School The majority of psychology students applying to graduate school are interested in clinical work, and approximately half of all graduate degrees in psychology are awarded in the subfields of clinical and counseling psychology (Mayne, Norcross, & Sayette, 2000). But deciding on a health care specialization in psychology gets complicated. The urgent question facing each student--and the question frequently posed to academic advisors--is "What are the differences between clinical psychology and counseling psychology?" Or, as I am asked in graduate school workshops, "What's the diff?" This article seeks to summarize the considerable similarities and salient differences between these two psychology subfields on the basis of several recent research studies. The results can facilitate your informed choice in the application process, enhance matching between the specialization and your interests, and sharpen the respective identities of psychology training programs. Considerable Similarities The distinctions between clinical psychology and counseling psychology have steadily faded in recent years, leading many to recommend a merger of the two. Graduates of doctoral- level clinical and counseling psychology programs are generally eligible for the same professional benefits, such as psychology licensure, independent practice, and insurance reimbursement. The American Psychological Association (APA) ceased distinguishing
    [Show full text]
  • Psychotherapy CPT Codes for Psychologists Services
    Documentation Guidelines Effective Date Psychotherapy CPT Codes for 7/17/17 Psychologists Services Revision Letter B Applies To: UNMMG 1.0 Purpose The American Medical Association (AMA) created new CPT codes in 2013 for Psychiatry, with guidance from the American Psychiatric Association. The UNMMG Medical Group, Inc. (UNMMG) follows the specific documentation and billing guidelines of the Centers for Medicare and Medicaid Services (CMS) when applicable. Non-compliance with these documentation requirements affects UNMMG’s ability to bill and receive appropriate reimbursement from the payers. This document provides specific guidelines for Psychologists only. 2.0 Scope This guidance applies to UNM Health System providers. See Paragraphs 4.0 through 4.6.4 below for the following CPT codes specific to Psychologists only. 3.0 Approved Providers for Mental Health Service In order for a Psychologist to qualify as a provider, the practitioner must meet the following requirements: o Hold a doctoral degree in psychology o Be licensed or certified on the basis of the doctoral degree in psychology by the state in which he/she practices, at the independent practice level of psychology to furnish diagnostic, assessment, preventive and therapeutic services directly to individuals. 4.0 Psychiatric Diagnostic Evaluation (90791) – (May be used by Psychologists) 4.1 Psychiatric Diagnostic Evaluation - 90791 This code is used for an initial diagnostic interview exam that does not include any medical services. The documentation should include a chief complaint, a history of present illness, communication with family or other sources, a psychosocial history, a complete mental status examination, and review and ordering of diagnostic studies.
    [Show full text]
  • 1 from Viktor Frankl's Logotherapy to the Four Defining Characteristics of Self-Transcendence (ST) Paul T. P. Wong Introductio
    1 From Viktor Frankl’s Logotherapy to the Four Defining Characteristics of Self-Transcendence (ST) Paul T. P. Wong Introduction The present paper continues my earlier presentation on self-transcendence (ST) as a pathway to meaning, virtue, and happiness (Wong, 2016), in which I introduced Viktor Frankl’s (1985) two-factor theory of ST. Here, the same topic of ST is expanded by first providing the basic assumptions of logotherapy, then arguing the need for objective standards for meaning, and finally elaborating the defining characteristics of ST. To begin, here is a common-sense observation—no one can remain at the same spot for life for a variety of reasons, such as developmental and environmental changes, but most importantly because people dream of a better life and want to move to a preferred destination where they can find happiness and fulfillment. As a psychologist, I am interested in finding out (a) which destination people choose and (b) how they plan to get there successfully. In a free society that offers many opportunities for individuals, there are almost endless options regarding both (a) and (b). The reality is that not all purposes in life are equal. Some life goals are misguided, such as wanting to get rich by any means, including unethical and illegal ones, because ultimately, such choices could be self-defeating—these end values might not only fail to fill their hearts with happiness, but might also ruin their relationships and careers. The question, then, is: What kind of choices will have the greatest likelihood of resulting in a good life that not only benefits the individual but also society? My research has led me to hypothesize that the path of ST is most likely to result in such a good life.
    [Show full text]
  • BIOEQUIVALENCE and STATISTICS in CLINICAL PHARMACOLOGY
    Interdisciplinary Statistics BIOEQUIVALENCE and STATISTICS in CLINICAL PHARMACOLOGY Scott Patterson GlaxoSmithKline Pharmaceuticals Pennsylvania, USA Byron Jones Pfizer Global Research & Development Kent, UK Chapman & Hall/CRC Taylor & Francis Croup Boca Raton London New York Contents Preface xi List of figures xiii List of tables xv 1 Drug Development and Clinical Pharmacology 1 1.1 Aims of This Book 2 1.2 Drug Development 3 1.3 Clinical Pharmacology 5 1.4 Statistics in Clinical Pharmacology 11 1.5 Structure of the Book 14 2 History and Regulation of Bioequivalence 17 2.1 When and How BE Studies Are Performed 19 2.2 Why Are BE Studies Performed? 27 2.3 Deciding When Formulations Are Bioequivalent 28 2.4 Potential Issues with TOST Bioequivalence 32 2.5 Current International Regulation 36 3 Testing for Average Bioequivalence 39 3.1 Background 39 3.2 Linear Model for 2 x 2 Data 44 3.3 Applying the TOST Procedure 49 3.4 Carry-over, Sequence, and Interaction Effects 52 3.5 Checking Assumptions Made about the Linear Model 56 3.6 Power and Sample Size for ABE in the 2x2 Design 58 3.7 Example Where Test and Reference Are Not ABE (il 3.8 Nonparametric Analysis 68 3.9 Some Practical Issues 76 4 BE Studies with More Than Two Periods 79 4.1 Background 80 4.2 Three-period Designs 81 viii CONTENTS 4.3 Within-subject Variability 87 4.4 Robust Analyses for Three Period Designs 90 4.5 Four-period Designs 92 4.6 Designs with More Than Two Treatments 96 4.7 Nonparametric Analyses of Tmax 102 4.8 Technical Appendix: Efficiency 116 4.9 Tables of Data 120
    [Show full text]